# Global Generics & BlCsimilars

AWARDS 2023

Wednesday, 25 October, 2023 | Hotel Porta Fira, Barcelona

# SUPPLEMENT



### Global Generics & BlCsimilars

**AWARDS 2023** 





As such, I would also like to congratulate each and every company and individual that submitted entries this year, all of which are worthy of recognition. Nominees have once again demonstrated the incredible breadth and depth of achievement across the global generics, biosimilars and value added medicines industries, and the massive contribution that the off-patent industry as a whole makes to global healthcare.

The Global Generics & Biosimilars Awards 2023 aims to recognize that valuable contribution, providing a showcase for the achievements of firms that develop, manufacture and market generics, biosimilars and value added medicines – as well as API producers, supply-chain partners, and other key players in supporting these industries.

And Generics Bulletin will continue to play our own part in supporting the industry by keeping you updated on all the key developments that you need to know about, as they happen.

Around 20 expert judges helped to decide these winners across our 14 categories, and as ever it has been a challenging task given the many and varied achievements that have been entered. We would like to thank our judges for their time, their expertise and their careful consideration.

Generics Bulletin would also like to thank our headline sponsor IQVIA, our welcome reception sponsor Sandoz, and our category sponsors Adalvo, Aurobindo, Parsity Group, Pharmacloud, Pharmawise, and West. We would also like to thank the Association for Accessible Medicines and its Biosimilars Council, the International Generic and Biosimilar Medicines Association and International Health Partners for their support of the event.

And finally, once again, our congratulations to this year's winners!

#### **David Wallace**

no mean feat.

Executive Editor, Generics Bulletin



## CONTENTS

| Sponsors and Winners List                                    | 4  |
|--|----|
| Company of the Year  | 5  |
| Company of the Year, Americas                                | 6  |
| Company of the Year, Asia-Pacific                            | 7  |
| Company of the Year, EMEA                                    | 8  |
| Value Added Medicine Initiative of the Year                  | 9  |
| Leader of the Year   | 11 |
| Business Development of the Year                             | 13 |
| Biosimilar Initiative of the Year                            | 15 |
| Regulatory Achievement of the Year                           | 17 |
| Campaign of the Year   | 18 |
| Industry Partner of the Year                                 | 19 |
| Acquisition of the Year                                      | 21 |
| Corporate Social Responsibility (CSR) Initiative of the Year | 23 |
| API Supplier of the Year                                     | 25 |
| Judging Panel  | 27 |
|  |    |

### WITH THANKS TO

#### **HEADLINE SPONSOR**



#### SPONSORS















#### SUPPORTED BY









#### COMPANY TABLES





SAMSUNG BIOFPIS

### WINNERS

The 2023 Global Generics & Biosimilars Awards were presented on Wednesday 25 October at the Hotel Porta Fira, Barcelona.

Awards winners are listed below:

Company of the Year Sponsored by IQVIA Sandoz

Company of the Year, **Americas** Dr. Reddy's Americas

Company of the Year,

Asia-Pacific Samsung Bioepis

Company of the Year, EMEA Accord Healthcare

Value Added Medicine **Initiative of the Year** Sponsored by IQVIA Sun Pharma

Leader of the Year Sponsored by Pharmacloud Richard Saynor, Sandoz

**Business Development** of the Year Sponsored by West Sandoz

**Biosimilar Initiative** of the Year Sponsored by Parsity Group Polpharma Biologics

**Regulatory Achievement** of the Year Samsung Bioepis

Campaign of the Year Biosimilars Canada -#MakeTheSwitch

**Industry Partner of the Year** Sponsored by Aurobindo Lambda Therapeutic Research

Acquisition of the Year Sponsored by Pharmawise **Biocon Biologics** 

**Corporate Social** Responsibility (CSR) Initiative of the Year - Supported by IHP Teva Pharmaceuticals

**Highly Commended:** Shanghai Henlius Biotech

API Supplier of the Year -Sponsored by Adalvo Olon Group

#### SAVE THE DATE:

Global Generics & Biosimilars Awards 2024 | Wednesday 9 October | Milan, Italy

#### **COMPANY OF THE YEAR**

#### SPONSORED BY $\equiv |\bigcirc \lor | \land$

#### WINNER: SANDOZ

The judges remarked that this is Sandoz's year, the year when it finally gains its independence and can demonstrate what it can do outside Novartis. The company successfully executed its spinoff from Novartis at the start of October and is now moving forward under the stewardship of 2023's leader of the year, Richard Saynor.



#### OTHER FINALISTS:

Accord Healthcare Biocon Biologics Celltrion Healthcare Samsung Bioepis STADA Celebrating your commitment to healthcare and improved patient outcomes

Congratulations to all the winners of the 2023 Global Generics and Biosimilars Awards



© 2023. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.

#### COMPANY OF THE YEAR, AMERICAS

#### WINNER: DR. REDDY'S AMERICAS

With a major presence across Latin American markets, Dr Reddy's has built up serious clout, including as the number one company represented in oncology across Brazil, Colombia and Chile, commented one of our judges. Its achievements in the Caribbean are also noteworthy, including by becoming the first company to launch four biosimilars in Jamaica.



#### OTHER FINALISTS:

Amneal Pharmaceuticals
Coherus BioSciences

#### COMPANY OF THE YEAR, ASIA-PACIFIC

#### WINNER: SAMSUNG BIOEPIS

One of our judges highlighted the enormous progress being made by this impressive company, suggesting that Samsung Bioepis are creating a strong brand and reputation in a market that is challenging and with highly complex products.

Samsung Bioepis continues to lead the way in biosimilars, commented another, pointing to the firm launching adalimumab in the US as well as obtaining a marketing authorization for Epysqli, a biosimilar to Soliris (eculizumab), in Europe. Also of note is that its Phase III clinical studies for its biosimilar candidates have been completed as planned or earlier than planned, including ustekinumab and an interchangeability study for adalimumab.



#### **OTHER FINALISTS:**

Aurobindo Pharma Beximco Pharma Biocon Biologics Shanghai Henlius Biotech Surge Laboratories

#### COMPANY OF THE YEAR, EMEA

#### WINNER: ACCORD HEALTHCARE

Accord Healthcare has established itself firmly as one of Europe's fastest growing pharmaceutical companies, commented one of our judges, pointing to achievements that included the firm becoming a leading supplier of G-CSF biosimilars in Europe as well the largest supplier of chemotherapy products in Europe.

Another pointed to some clear and unique initiatives in 2023 – such as geographical expansion and an entry into animal health – as well as the focus on people and putting accessible medicine at the forefront of its strategy.



#### **OTHER FINALISTS:**

Sandoz STADA

### VALUE ADDED MEDICINE INITIATIVE OF THE YEAR

#### SPONSORED BY $\equiv |\bigcirc \lor | \land$

#### WINNER: SUN PHARMA

The launch of Sezaby – the only FDAapproved and only preservative-free phenobarbital for neonatal seizures – was an important achievement and a great initiative, according to our judges.



#### OTHER FINALISTS:

Collected on behalf of Sun Pharma

Accord Biopharma Adalvo Cadila Pharmaceuticals PharmEvo Zentiva – Dasatinib Zentiva – Omeprazole

#### LEADER OF THE YEAR

#### SPONSORED BY



#### WINNER: RICHARD SAYNOR, SANDOZ

One of our judges highlighted an impressive number of achievements for Saynor, adding that Richard continues to be a driver of all Sandoz' values.

Richard has done a sterling job of steering Sandoz towards independence, commented another, suggesting that he will now be able to show what he can do once Sandoz is no longer part of Novartis.



#### **OTHER FINALISTS:**

Anil Okay, Adalvo Apurva Saraf, Cosette Pharmaceuticals Paul Tredwell, Accord Healthcare EMENA Peter Goldschmidt, STADA Rachel Goode, Fresenius Kabi

## Pharmacloud

**Commercial DD: Research Market Mapping** 



www.pharmacloud.co.uk

#### BUSINESS DEVELOPMENT OF THE YEAR

#### SPONSORED BY (100



#### WINNER: SANDOZ

One of our judges called this alliance a commendable deal, adding that they would be awaiting results of the collaboration.

Another suggested that Sandoz was simply the best in bio, year by year, while yet another pointed to the agreement as an interesting collaboration with the use of AI.



#### OTHER FINALISTS:

Accord Healthcare Adalvo Aurobindo Pharma Biocon Similis Bio Zentiva

### **Congratulations**

to all of the finalists and winners of the

2023 Global Generics and Biosimilar Awards

West is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients.

LEARN MORE ABOUT WEST AT **WESTPHARMA.COM** 

West and the diamond logo is a registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.

Copyright © 2023 West Pharmaceutical Services, Inc.



West €

#### BIOSIMILAR INITIATIVE OF THE YEAR

SPONSORED BY



#### WINNER: POLPHARMA BIOLOGICS

One of our judges described this winning entry as a strong submission with the satisfaction of patient unmet need at its core.

Another said the approval represented a significant achievement for Polpharma Biologics' burgeoning biosimilars business and for patients across the US and Europe that will enjoy broader access to a vital drug to treat MS.



#### OTHER FINALISTS:

Accord Healthcare Celltrion Healthcare Lambda Therapeutic Research Samsung Bioepis Sandoz Similis Bio



## Congratulations

to all the finalists and winners of the 2023 Global Generics and Biosimilars Awards!



**Connecting Excellence in Generics and Biosimilars** 

We are a leading modern executive search for the generics, biosimilars and speciality pharmaceutical industries.

#### REGULATORY ACHIEVEMENT OF THE YEAR

#### WINNER: SAMSUNG BIOEPIS

The firm's approval of seven biosimilar products in Europe and six in the US make this a winner, commented one of our judges, while another pointed to the firm's impressive accomplishments.

Samsung Bioepis' success in this category was largely based on doing the day job well, but demonstrating some positive achievements in a difficult area.



#### **OTHER FINALISTS:**

Adalvo Ami Lifesciences Aurobindo Pharma Dr. Reddy's Laboratories Zentiva

#### CAMPAIGN OF THE YEAR

### WINNER: BIOSIMILARS CANADA - #MAKETHESWITCH

This was an excellent campaign which resulted in a change in policy and significant savings for the Canadian health system, commented one of our judges, with another pointing to the success of the campaign: Ontario has indeed implemented a switching policy.

Another said there was no doubt that this has been a huge political and strategic undertaking, which appears to have been implemented successfully.

#### **OTHER FINALISTS:**

Association for Accessible Medicines – #4GRXANTED
Canadian Generic Pharmaceutical Association – #PrescriptionForCanada
Celltrion Healthcare – "Where's CC (Crohn's & Colitis)?" Campaign
International Generic and Biosimilar Medicines Association – Global Biosimilars Week
Campaign
Samsung Bioepis – "Why Biosimilars" Campaign

Sandoz – Act4Biosimilars Action Plan

#### INDUSTRY PARTNER OF THE YEAR

#### SPONSORED BY



#### WINNER: LAMBDA THERAPEUTIC RESEARCH

This entry's innovative assays introduce novel approaches and techniques to overcome specific challenges in bioanalysis and exceed the most stringent regulatory expectations from agencies like USFDA and EMA, summarized one of our judges.



#### OTHER FINALISTS:

Adalvo
Affygility Solutions
Biocon
Centrient Pharmaceuticals and Ginkgo Bioworks
Inoviem Scientific
Surge Laboratories

### Aurobindo Pharma - Snapshot

#1 #2

Largest Generic Pharma Company in the US (by Rx dispensed) \*

Second largest listed Indian Pharma Company (by FY23 operating revenue)

#10

#46

Amongst top 10 generic companies in 8 countries of Europe®

Rank among global pharma companies<sup>^</sup>



Dosage forms manufactured in **FY23** 

Exporting to 150+ countries



**41** \$3.1Bn


Global revenue in FY23

90% revenue



Manufacturing & Packaging units globally

15 Formulations & 10 API facilities



Global employee strength

1.500+ R&D team size



**R&D** centers 5 in India 4 in US

**774** ANDA filings in US#



5.7%

of revenue spent on R&D in FY23

Total R&D spend \$176Mn

Committed to becoming one of the most sustainable organizations in the pharmaceutical industry

#### **ACQUISITION OF THE YEAR**



#### WINNER: BIOCON BIOLOGICS

This was a very good entry highlighting a hugely significant acquisition, commented one of our judges. Not only is this big in terms of strategic and corporate value now, but it will clearly provide a world-leading platform to exploit the boom in biosimilars as exclusivities expire in the coming years.



#### OTHER FINALISTS:

Adalyo **Rising Pharmaceuticals** Sandoz **7entiva** 



#### Pharmawise: Your Gateway to Genuine Expert Advisory

Pharmawise expertise has underpinned over 250 projects, supporting \$20B+ in company and product value, all powered by our unparalleled network of industry experts.

"Genuine Expert Advisory," isn't just words—it's our promise.

Tailored for private equity and strategic investors, we transform the intricacies of the pharmaceutical landscape into actionable insights. We decode the complexities of pharma, ensuring your investments are expertly guided.

Let's elevate your venture with our seasoned experts.

Illuminate your path and start the dialogue.



CORPORATE SOCIAL RESPONSIBILITY (CSR) INITIATIVE OF THE YEAR

### SUPPORTED BY



#### WINNER: TEVA **PHARMACEUTICALS**

Teva took great care to understand the mental health crisis in the US and developed an exceptional partnership with Direct Relief to address the problem, develop some clear objectives and provide some solutions. Mental Health is incredibly underfunded and served in human health, so it is refreshing to see an organisation looking to improve access to mental health services for patients. The programme is unique and Teva have demonstrated some good results and they stood out as having additional unintended benefits for minority groups.



#### **HIGHLY COMMENDED:** SHANGHAI HENLIUS BIOTECH

This is an innovative initiative which is clearly patient focused, commented our judges. The company has made a significant investment to make the programme successful and sustainable and their actions reflect their mission to serve all patients in need. Henlius are clearly aware of the challenge patients living in rural villages can face and seek to improve their chances when diagnosed as HER-2 positive. The entry has clear objectives and actions to achieve them. The initiative provides a lasting impact as a result of the training and education provided to doctors in Chinese rural villages. The quantitative results also provide evidence that the initiative is having a very positive impact.

#### OTHER FINALISTS:

Accord Healthcare

Centrient Pharmaceuticals

Dr. Reddy's Laboratories

**Furofarma** Laboratórios







### At least two billion people worldwide live without reliable access to essential medicines.

International Health Partners (IHP) exists to change this by managing quality medical donations effectively and efficiently, supporting International Development NGOs, and enabling pharmaceutical company giving.

IHP proudly sponsors the GGB 'CSR Initiative of the Year Award'. We have been working with pharmaceutical companies for 20 years to help realise their CSR ambitions.

Together, we can do more to enable access to healthcare for the world's most vulnerable. For more information contact Emma Shepherd: e.shepherd@ihpuk.org





#### API SUPPLIER OF THE YEAR



WINNER: OLON GROUP

Highlighting the potential of Olon's important investment, our judges said the new plant opened in 2023 with an investment of €10m was an important milestone.

#### OTHER FINALISTS:

MSN Laboratories Neuland Laboratories Piramal Pharma Solutions R L Fine Chem Solara Active Pharma Sciences




Adalvo has become a successful launch engine where we are executing launches

- For over 250 new SKUs globally
- With more than 65 partners
- In over 60 markets

Within 2023 alone!

We are extremely focused on securing launches on MA approval for each product, partner and territory.

Partner up now and join us in our journey!



### JUDGING PANEL

Our commitment to awards entrants and attendees is bound up in the selection of judges who volunteer their time, experience, and consideration of the hundreds of entries to our various annual global awards.

The judges, invited from the generics and biosimilars industries, engage in the judging process independently, combining their industry knowledge to evaluate entries against the entry criteria. We are careful to ensure that each judge only reviews categories where there are no conflicts of interest.

Without judges' depth of knowledge and passion for supporting the two industries, the Global Generics & Biosimilars Awards would not be possible. We take this opportunity to thank all our judges for their role in helping to ensure the integrity of the Global Generics & Biosimilars Awards.

#### **AURELIO ARIAS**

Director, EMEA Thought Leadership, IQVIA

#### STUART COLLIGON

Managing Director, Auxesia

#### FRANCES CLOUD

Managing Director, Pharmacloud

#### DUNCAN EMERTON

Executive Director, Customer Intelligence & Analytics, Citeline

#### VIVIAN FRITELLI

Chief Executive Officer, Generic and Biosimilar Medicines of Southern Africa

#### CHLOE KENT

Senior Reporter, Generics Bulletin

#### JIM KEON

President, Canadian Generic Pharmaceutical Association

#### SUZETTE KOX

Secretary General, International Generic and Biosimilar Medicines Association

#### **EWAN LIVESEY**

Founder and Managing Director, Birnam Oak Consultancy

#### MARNIE PETERSON

Chief Executive Officer, Generic and Biosimilar Medicines Association

#### AXEL MULLER

Associate Partner, Fidelio Healthcare Partners

#### **DEAN RUDGE**

Deputy Editor, Generics Bulletin

#### ADRIAN VAN DER HOVEN

Director General, Medicines for Europe

### JAMES VANE TEMPEST

Managing Director, Jefferies International

#### DAVID WALLACE

Executive Editor, Generics Bulletin

Judging of the Corporate Social Responsibility Initiative of the Year category was by International Health Partners

## SAVE THE DATE

Global Generics & Biosimilars Awards **2024** Wednesday 9 October Milan, Italy